InVivo Therapeutics Holdings Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVIV research report →
Price Chart
About the company
InVivo Therapeutics Holdings Corp. is a biotechnology and biomaterials firm, actively involved in research and clinical development. The company specializes in creating and bringing to market innovative biopolymer scaffolding devices designed to address spinal cord injuries (SCI).
- CEO
- Richard M. Toselli
- IPO
- 2010
- Employees
- 6
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on NVIV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $995.92K
- P/E
- -0.05
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.03
- EV/EBITDA
- 1.46
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -60.12%
- ROIC
- -63.58%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-445,000-19.6%
- Op Income
- $-10,650,000
- Net Income
- $-10,179,000-2.9%
- EPS
- $-6.62+11.4%
- OCF Growth
- -18.4%
- FCF Growth
- -19.2%
- 52W High
- $2.40
- 52W Low
- $0.22
- 50D MA
- $0.70
- 200D MA
- $1.05
- Beta
- 0.66
- RSI (14)
- 38
- Avg Volume
- 3.77M
No earnings-call transcripts are available for NVIV yet.
- Free Float
- 99.7%
- Shares Outstanding
- 3.11M
- Float Shares
- 3.10M
of shares held by institutions
14 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 5, 23 | Foose Brice | sell | 37,000 |
| Feb 5, 23 | Foose Brice | sell | 20,000 |
| Feb 5, 23 | Foose Brice | sell | 13,000 |
| Feb 5, 23 | Foose Brice | sell | 48,000 |
| Feb 5, 23 | Foose Brice | sell | 12,000 |
| Feb 5, 23 | Foose Brice | sell | 36,000 |
| Feb 6, 23 | Foose Brice | sell | 8,000 |
| Feb 6, 23 | Foose Brice | sell | 33,000 |
| Feb 6, 23 | Foose Brice | sell | 35,000 |
| Feb 6, 23 | Foose Brice | sell | 37,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NVIV coverage
Recent articles, reports, and earnings notes.
No research on NVIV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NVIV report →Why Is InVivo Therapeutics (NVIV) Stock Up 61% Today?
investorplace.com · Feb 6
Why Is InVivo Therapeutics (NVIV) Stock Down 34% Today?
investorplace.com · Oct 7
7 Biotech Stocks to Buy That Have Millionaire-Maker Potential
investorplace.com · Sep 10
InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study
businesswire.com · Sep 8
3 Biotech Penny Stocks That You Need to Know About In 2021
pennystocks.com · Jul 20
Best Penny Stocks To Watch For July 2021
pennystocks.com · Jul 14
NVIV Stock Increases Over 36% Intraday: Why It Happened
pulse2.com · Jul 13
InVivo Therapeutics Stock Moves Higher On FDA Acceptance Of Preclinical Module For Neuro-Spinal Implant
benzinga.com · Jul 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.